№ lp_1_2_36188
File format: docx
Character count: 4534
File size: 73 KB
This document outlines the procedures and criteria for dose escalation in clinical trials, including data verification, participant management, and risk mitigation.
Year:
Not specified
Region / city:
Not specified
Theme:
Clinical Trials, Dose Escalation
Document type:
Protocol
Organization / institution:
Not specified
Author:
Not specified
Target audience:
Clinical researchers, Principal Investigators
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / City:
Mayo, Ireland
Subject:
Nursing, Emergency & Acute Medicine
Document Type:
Job Specification
Organization:
Mayo University Hospital
Author:
Not specified
Target Audience:
Nurses, Healthcare professionals
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Year
Topic:
Education Quality Assurance
Document Type:
Guideline
Target Audience:
Educators, assessors, clinical staff
Note:
Year
Topic:
Behaviour Management
Document Type:
Behaviour Response Plan
Organization / Institution:
Autism Spectrum Australia
Target Audience:
Educators, Support Staff, School Staff
Type of document:
School attendance procedure
Subject:
Student absence escalation and attendance monitoring
Sector:
Education
Audience:
School staff and attendance leads
Geographic reference:
Hackney
Responsible bodies:
School, Local Authority, Attendance Service, Children’s Social Care
Key actions:
Contact attempts, home visits, letters, referrals, penalty notices
Timeframe covered:
Days 1–10 of continuous absence
Attendance thresholds:
96% to below 90%
Safeguarding considerations:
Vulnerable children, safeguarding lead involvement
Source type:
Administrative guidance
Note:
Year
Note:
Year
Region / City:
Central Norfolk
Theme:
Health and Social Care
Document Type:
Referral Guidelines
Institution:
NEAT
Target Audience:
Health and social care professionals
Year:
2023
Region / City:
Hawke’s Bay, New Zealand
Theme:
Gout management, pharmacology
Document type:
Standing Order
Organisation / Institution:
Te Whatu Ora – Health New Zealand, Te Matau a Māui Hawke’s Bay Mate Taihā Service
Author:
Te Whatu Ora – Hawke’s Bay
Target audience:
Pharmacists, Medical Practitioners, Nurse Practitioners
Validity period:
Issued: (not specified), Review date: (not specified)
Approval date:
(not specified)
Date of changes:
(not specified)
Scope:
Allopurinol dose escalation for gout management in Māori men over 17 years old with specific eligibility criteria
Medicine:
Allopurinol 100mg and 300mg tablets
Route of administration:
Oral
Indication for activating standing order:
Patient meets inclusion criteria for gout management
Indication for terminating the standing order:
Serum urate levels stabilised after dosing escalation
Precautions:
Exclusions for patients with specific conditions or risks
Note:
Context
Year:
2024
Region / City:
Canberra
Topic:
Maternity, Medical Procedures
Document Type:
Procedure
Organization / Institution:
Canberra Health Services
Author:
N/A
Target Audience:
Healthcare staff (Midwives, Medical Officers)
Effective Period:
Ongoing
Approval Date:
19/02/2024
Amendment Date:
19/02/2024
Note:
Year
Topic:
Safeguarding Adults, Dispute Resolution
Document Type:
Procedure
Organization / Institution:
Bristol Safeguarding Adults Board (BSAB)
Target Audience:
Professionals involved in safeguarding adults
Contextual description:
Form used to document the process and outcomes of the Escalation Policy for resolving disputes within safeguarding procedures for adults at risk.
Year:
2023
Region / City:
Canberra
Topic:
Physiological deterioration, medical escalation, healthcare services
Document Type:
Guideline
Organization / Institution:
Canberra Health Services
Author:
Unknown
Target Audience:
Clinical staff within Canberra Health Services Network
Effective Period:
Ongoing
Approval Date:
2023
Date of Changes:
Not specified
Note:
Year
Topic:
Safeguarding children, Professional Disagreements
Document Type:
Practice Guidance
Organization / Institution:
Newcastle Safeguarding Children Partnership
Target Audience:
Professionals in safeguarding children, including Voluntary, Community and Faith sectors
Contextual description:
A practice guidance document outlining the steps for resolving professional disagreements in safeguarding children, focusing on inter-agency processes for the protection of children’s welfare.
Year:
2026
Region / city:
England
Subject:
NHS Standard Contract, Escalation Process
Document type:
Form
Organization:
NHS England
Author:
NHS Standard Contract team
Target audience:
Healthcare providers and commissioners
Validity period:
January 2026
Approval date:
January 2026
Date of changes:
Not specified
Date of publication:
January 2026
Note:
Contextual description
Year:
2026
Region / City:
South Brisbane
Topic:
Victim Support, Youth Justice
Document Type:
Job Advertisement
Agency:
Department of Youth Justice and Victim Support
Author:
Department of Youth Justice and Victim Support
Target Audience:
Job applicants for the Senior Review Officer position
Period of Validity:
Until 30 June 2026
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2006
Region / City:
Australia
Topic:
Medication management, disability services
Document Type:
Legal / Regulatory
Organization:
Disability Services
Author:
Not specified
Target Audience:
Healthcare providers, professionals in disability services
Effective Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2023
Region / City:
Australia
Subject:
Chronic migraine, medicinal product submission
Document type:
Submission for PBS listing
Organization:
Novartis Pharmaceuticals Australia Pty. Limited
Author:
Not specified
Target audience:
Health professionals, pharmaceutical regulatory bodies
Period of validity:
Not specified
Date of approval:
2 July 2018
Date of amendments:
November 2023
Year:
2024
Regulatory authority:
Therapeutic Goods Administration (TGA)
Medicine:
MACITENTAN 10 mg with TADALAFIL 40 mg (Opsynvi®)
Indication:
Pulmonary arterial hypertension (PAH), WHO Group 1, functional class II and III
Therapy type:
Dual or triple combination therapy
Dosage form:
Tablet, fixed dose combination (FDC)
Prescriber type:
Medical practitioners
Restriction type:
Authority Required (Written, Complex Authority Required)
Clinical criteria:
Treatment as dual therapy (MAC+TAD) or triple therapy with prostanoid
Population:
Adult patients with stable PAH on separate doses of macitentan and tadalafil
Previous considerations:
PBAC recommendations for macitentan and tadalafil since 2011–2014
Approval date:
16 September 2024
Source documents:
TGA registration, PBAC meeting minutes, ACM minutes August 2024, FDA, EMA, CDA references
Note:
Year
Subject:
High Dose Antipsychotic Monitoring
Document Type:
Medical Form
Institution:
Oxford Health
Target Audience:
Healthcare professionals
Year:
2024
Region / city:
United Kingdom
Subject:
Radiological Protection, Transport of Radioactive Materials
Document Type:
Technical Assessment Guide
Organization:
Office for Nuclear Regulation (ONR)
Author:
Inspector - Nuclear Safety
Target Audience:
ONR safety inspectors
Validity Period:
October 2024 - October 2029
Approval Date:
October 2024
Revision Date:
Not applicable
Document Reference:
NS-TAST-GD-100
Record Reference:
2020/281169
Issue:
2.1
Purpose:
Guidance for assessing shielding designs and dose rates of transport packages for radioactive materials.
Scope:
Focuses on shielding and dose rate assessments in accordance with IAEA regulations for transport safety.
Related Legislation:
IAEA SSR-6 (2018), UK regulations for radioactive materials transport
Note:
Contextual Description